GlassScriptPhysician profile
Antonio D Ramos
NPI 1760554737
$1,887.97
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $301 · 2021: $287 · 2022: $496.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,081.59 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $182.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $178.08 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $107.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $90.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $75.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.59 | 2019-2021 | |
| Pfizer INC. | $50.15 | 2021 | |
| Lilly USA, LLC | $27.90 | 2022 | |
| Abbvie INC. | $27.51 | 2022 | |
| Glaxosmithkline, LLC. | $13.61 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.